NCT05147792暂停不适用
An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 入组人数
- 1,600
- 试验地点
- 242
- 主要终点
- Ischemic stroke and systemic embolism
研究概览
简要总结
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant female aged ≥18 years
- •Documented non-valvular AF (paroxysmal, persistent, or permanent)
- •High risk of stroke or systemic embolism, defined as CHA2DS2-VASc score of ≥ 3
- •Has an appropriate rationale to seek a non-pharmacologic alternative to long-term oral anticoagulation
- •Deemed by the site investigator to be suitable for short term oral anticoagulation therapy but deemed less favorable for long-term oral anticoagulation therapy.
- •Deemed appropriate for LAA closure by the site investigator and a clinician not a part of the procedural team using a shared decision-making process in accordance with standard of care
- •Able to comply with the protocol-specified medication regimen and follow-up evaluations
- •The subject (or legally authorized representative, where allowed) has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate institutional review board (IRB)/Regional Ethics Board (REB)/Ethics Committee (EC).
排除标准
- •Pregnant or nursing patients and those who plan pregnancy in the period up to one year following the index procedure. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to index procedure.
- •Anatomic conditions that would prevent performance of an LAA occlusion procedure (e.g., atrial septal defect (ASD) requiring closure, high-risk patent foramen ovale (PFO) requiring closure, a highly mobile inter-atrial septal aneurysm precluding a safe TSP, presence of a PFO/ASD closure device, history of surgical ASD repair or history of surgical LAAO closure)
- •Atrial fibrillation that is defined by a single occurrence or that is transient or reversible (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
- •A medical condition (other than atrial fibrillation) that mandates long-term oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or prosthetic mechanical heart valve)
- •History of bleeding diathesis or coagulopathy, or patients in whom antiplatelet and/or anticoagulant therapy is contraindicated
- •Documented active systemic infection
- •Symptomatic carotid artery disease (defined as >50% stenosis with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is <50% stenosis noted at the site of prior treatment
- •Recent (within 30 days of index procedure) or planned (within 60 days post-procedure) cardiac or major non-cardiac interventional or surgical procedure
- •Recent (within 30 days of index procedure) stroke or transient ischemic attack
- •Recent (within 30 days of index procedure) myocardial infarction
- •Vascular access precluding delivery of implant with catheter-based system
- •Severe heart failure (New York Heart Association Class IV)
- •Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any prosthetic mechanical valve implant
- •Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation)
- •Platelet count <75,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3
- •Known allergy, hypersensitivity or contraindication to aspirin, heparin, or that would preclude any P2Y12 inhibitor therapy, or to device materials (e.g., nickel, titanium), or the subject has contrast sensitivity that cannot be adequately pre-medicated
- •Actively enrolled or plans to enroll in a concurrent clinical study in which the active treatment arm may confound the results of this trial
- •Unable to undergo general anesthesia
- •Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 5 years
- •A condition which precludes adequate transesophageal echocardiographic assessment
- •Echo exclusion criteria:
- •Left atrial appendage anatomy which cannot accommodate a commercially available control device or the CLAAS Implant per manufacturer IFU (e.g., the anatomy and sizing must be appropriate for both the investigational (CLAAS) and a commercially available device in order to be enrolled in the trial)
- •Intracardiac thrombus or dense spontaneous echo contrast consistent with thrombus, as visualized by TEE
- •Left ventricular ejection fraction (LVEF) <30%
- •Moderate or large pericardial effusion >10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology
- •Atrial septal defect that warrants closure
- •High risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion >15 mm or length > 15 mm) or large shunt (early [within 3 beats] and/or substantial passage of bubbles, e.g., >20)
- •Moderate or severe mitral valve stenosis (mitral valve area <1.5 cm2)
- •Complex atheroma with mobile plaque of the descending aorta and/or aortic arch
- •Evidence of cardiac tumor
研究组 & 干预措施
CLAAS
Experimental
Transcatheter left atrial occluder
干预措施: CLAAS (Device)
WATCHMAN / Amulet
Active Comparator
Transcatheter left atrial occluder
干预措施: WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder (Device)
结局指标
主要结局
Ischemic stroke and systemic embolism
时间窗: 18 months
The primary effectiveness endpoint is a composite of ischemic stroke and systemic embolism through 18 months.
Procedure-related complications, all-cause death, major bleeding
时间窗: 12 months
The primary safety endpoint is a composite of 1) major procedure-related complications including a) cardiac perforation, b) pericardial effusion requiring drainage, c) ischemic stroke, d) device embolization, and e) major vascular complications, or 2) major bleeding, or 3) all-cause death
次要结局
- Closure Success(12 months)
- Procedure-related complications, all-cause death, major bleeding(5 years)
- Device Success(Procedure)
- Technical success(45 days)
- Procedure success(7 Days)
- Embolic Events(12 Months, 18 Months)
- All Cause Mortality(18 months)
- Myocardial Infarction(7 days)
- Neurologic Events(45 days)
- Closure Success(12 months)
研究者
研究点 (242)
Loading locations...
相似试验
进行中（未招募）
不适用
Clinical study of the safety and effectiveness of the use of a hyaluronic acid injectable product (Perfectha® Finelines Lidocaine) in the treatment of wrinkles around the eyes and mouthISRCTN16392182Sinclair Pharmaceuticals Limited69
进行中（未招募）
不适用
Assessment of the safety, efficacy, tolerability and pharmacokinetics of PegIntron plus Rebetol in pediatric patients with chronic hepatitis C.EUCTR2004-000558-22-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron Plus REBETOL for Pediatric Patients with Chronic Hepatitis CEUCTR2004-000558-22-ESSchering-Plough Research Insitute107
进行中（未招募）
1 期
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12
已完成
1 期
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN)M32.1Systemic lupus erythematosus with organ or system involvementDRKS00004858Charité - Universitätsmedizin Berlin10